Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476750 | 0.95 | NR3C1 (0.80) | NR3C1 | |
| SCHEMBL476727 | 0.94 | NR3C1 (0.86) | NR3C1 | |
| SCHEMBL476774 | 0.94 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL476777 | 0.92 | NR3C1 (0.86) | NR3C1 | |
| SCHEMBL476722 | 0.91 | NR3C1 (0.84) | NR3C1 | |
| SCHEMBL476717 | 0.91 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL476773 | 0.91 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL476757 | 0.89 | NR3C1 (0.78) | NR3C1 | |
| SCHEMBL476783 | 0.89 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL476753 | 0.89 | NR3C1 (0.90) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2081910-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120883-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | NR3C1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.